Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0686 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| MK0686 | DRUG | - |
Inclusion Criteria: * Patients with a clinical and radiographic diagnosis of osteoarthritis of the hip or knee,either prior NSAID or Acetaminophen users within the ARA functional class I,II or III and with no clinically significant diseases * Patients required to demonstrate a flare of the signs an...
MK0686 is an investigational small molecule being studied for the treatment of pain, including postoperative pain and osteoarthritis. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
MK0686 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
MK0686 is in Phase 2 clinical development. Clinical trials for this investigational drug have been completed, and it remains under study for pain-related conditions. It is not approved for commercial use.
MK0686 has been studied in two completed Phase 2 clinical trials. One trial, NCT00296569, enrolled 150 patients with osteoarthritis. Another trial, NCT00533403, enrolled 114 patients with postsurgery dental pain.
Yes, MK0686 is also referred to as MK-686. Clinical trial records use both names to describe the same investigational drug being developed by Merck & Company, Inc. for pain and osteoarthritis.